Tyme Technologies Inc Stock News

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they ha

-- $84.0 million in cash and marketable securities as of March 31, 2022 -- -- $84.0 million in cash and marketable securities as of March 31, 2022 --

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMB

Tyme Technologies Inc. TYME, -5.56% , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis & Co. as a finan

-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation April

Tyme Technologies Inc. (NASDAQ:TYME) shares, rose in value on Friday, 02/18/22, with the stock price down by -0.32% to the previous days close as strong demand from buyers drove the stock to $0.34. Actively observing the price movement in the last trading, the stock closed the session at $0.34, falling within a range of $0.3305 The Tyme Technologies Inc. (NASDAQ: TYME) Stock Price: Is It Overvalued? Read More »

Although US crude futures fell over 2% on Thursday, there were a few notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospe

Tyme Technologies press release (TYME): FQ3 GAAP EPS of -$0.03.The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s…

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™),

Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaz

TYME Technologies Inc (NASDAQ: TYME ) will discontinue SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC). The trial''s sponsor, Pancreatic Cancer Action Network (PanCAN), terminated the arm due to futility compared to the control of the standard of Full story available on Benzinga.com

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss biotech Molecular Par